[Long-term cross-circulation on galactosamine induced hepatic failure rats]

Area of Science:

• Hepatology
• Mitochondrial Physiology
• Surgical Research

Background:

• Galactosamine-induced liver failure in rats serves as a model for studying acute liver injury.
• Mitochondrial dysfunction is a key pathological feature in hepatic failure, leading to impaired energy production.
• Current therapeutic options for acute liver failure remain limited, necessitating novel approaches.

Purpose of the Study:

• To evaluate the efficacy of cross-circulation in supporting liver function during galactosamine-induced hepatic failure.
• To assess the impact of cross-circulation on mitochondrial respiratory function and energy supply in the liver.
• To determine the effect of cross-circulation on the survival rate of rats with hepatic failure.

Main Methods:

• Hepatic failure was induced in rats via galactosamine injection.
• Cross-circulation was established between galactosamine-treated rats and normal rats for 8 hours at a blood flow rate of 1 ml/min.
• Mitochondrial respiratory function, including ATP synthesis, phosphorylation turnover number, and Cytochrome a (+a3) levels, was measured.
• Survival rates were monitored at 48 and 60 hours post-galactosamine injection.

Main Results:

• The cross-circulation group exhibited significantly higher survival rates (86% at 48h, 57% at 60h) compared to the sham-circulation group (66% at 48h, 23% at 60h).
• Significant increases in ATP synthesis per 100g body weight, phosphorylation turnover number, and Cytochrome a (+a3) were observed in the cross-circulation group.
• These parameters were markedly reduced in the sham-circulation group, indicating impaired mitochondrial function.

Conclusions:

• Cross-circulation effectively augments mitochondrial energy supply to the liver in a model of galactosamine-induced hepatic failure.
• The enhanced mitochondrial function directly correlates with improved survival rates in rats undergoing cross-circulation.
• Cross-circulation represents a promising supportive therapy for acute liver failure by restoring hepatic energy metabolism.